Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Erlander · SciRah

Researcher profile · Semantic Scholar

M. Erlander

Share profile

M. Erlander — researcher profile on SciRah

h-index: 57
Works: 220
Citations: 16K

Most-cited papers

Prediction of late distant recurrence in estrogen receptor positive breast cancer patients: prospective comparison of the Breast Cancer Index (BCI), Oncotype DX recurrence score, and IHC4 in TransATAC
D. Sgroi, I. Šestak, J. Cuzick, Yi Zhang +8 more
2013The Lancet Oncology388 citations Open access
Semantic Scholar
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
K. Reckamp, V. Melnikova, C. Karlovich, L. Sequist +17 more
2016Journal of Thoracic Oncology273 citations Open access
Semantic Scholar
Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
Yi Zhang, C. Schnabel, B. Schroeder, Piiha-Lotta Jerevall +6 more
2013Clinical Cancer Research237 citations
Semantic Scholar
Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
D. Hyman, E. Diamond, C. Vibat, Latifa Hassaine +16 more
2014Cancer Discovery132 citations Open access
Semantic Scholar
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine
H. Husain, V. Melnikova, K. Kosco, B. Woodward +9 more
2017Clinical Cancer Research120 citations Open access
Semantic Scholar
Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies.
Veena M. Singh, R. Salunga, Vivian J Huang, Y. Tran +3 more
2013Annals of Diagnostic Pathology120 citations
Semantic Scholar
BRAFV600E Mutations in High Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy
S. Klempner, B. Gershenhorn, P. Tran, Thomas K. Lee +9 more
2016Cancer Discovery86 citations Open access
Semantic Scholar
Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors.
L. Weiss, P. Chu, B. Schroeder, Veena M. Singh +3 more
2013Journal of Molecular Diagnostics76 citations Open access
Semantic Scholar
Development and validation of a 32-gene prognostic index for prostate cancer progression
Chin-Lee Wu, B. Schroeder, Xiao-Jun Ma, Christopher J. Cutie +7 more
2013Proceedings of the National Academy of Sciences of the United States of America72 citations Open access
Semantic Scholar
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
A. Zeidan, M. Ridinger, Tara L. Lin, P. Becker +8 more
2020Clinical Cancer Research69 citations Open access
Semantic Scholar
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
F. Janku, C. Vibat, K. Kosco, Veronica R. Holley +9 more
2014OncoTarget64 citations Open access
Semantic Scholar
Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer.
V. Senkomago, A. D. Des Marais, L. Rahangdale, C. R. T. Vibat +2 more
2016Journal of Clinical Virology58 citations Open access
Semantic Scholar
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
T. Fujii, A. Barzi, A. Sartore-Bianchi, A. Cassingena +21 more
2017Clinical Cancer Research52 citations Open access
Semantic Scholar
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease
L. Habel, L. Sakoda, N. Achacoso, Xiao-Jun Ma +5 more
2013Breast Cancer Research44 citations Open access
Semantic Scholar
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
A. Giordano, Yueying Liu, K. Armeson, Yeonhee Park +7 more
2019PLoS ONE42 citations Open access
Semantic Scholar
Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population
J. Cuzick, L. Cadman, A. Ahmad, L. Ho +10 more
2017Cancer Epidemiology, Biomarkers and Prevention42 citations Open access
Semantic Scholar
Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma
I. Chen, V. Raymond, J. Geis, E. Collisson +5 more
2017OncoTarget35 citations Open access
Semantic Scholar
A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors
S. Kerr, C. Schnabel, P. Sullivan, Yi Zhang +4 more
2014Modern Pathology35 citations Open access
Semantic Scholar
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
G. Siravegna, A. Sartore-Bianchi, Benedetta Mussolin, A. Cassingena +11 more
2017Annals of Oncology33 citations Open access
Semantic Scholar
Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
H. Wakelee, S. Gadgeel, J. Goldman, K. Reckamp +15 more
201633 citations
Semantic Scholar
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Dong Wang, Bethany L. Veo, Angela M. Pierce, S. Fosmire +11 more
2021Neuro-Oncology32 citations Open access
Semantic Scholar
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
N. Tchekmedyian, R. Mudad, F. Blanco, V. Raymond +4 more
2017Lung Cancer25 citations
Semantic Scholar
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
J. C. Patterson, Andreas Varkaris, P. Croucher, M. Ridinger +15 more
2022Cancer Research24 citations Open access
Semantic Scholar
Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
D. Berz, V. Raymond, Jordan H. Garst, M. Erlander
2016Experimental Hematology & Oncology21 citations Open access
Semantic Scholar
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers.
Xiaolong Wang, Bing-Sheng Li, A. Ciotkowska, B. Rutz +7 more
2020European Journal of Pharmacology20 citations
Semantic Scholar
High-Risk Human Papillomavirus Detection in Urine Samples From a Referral Population With Cervical Biopsy-Proven High-Grade Lesions
A. Lorenzi, J. Fregnani, J. Dockter, K. Fitzgerald +7 more
2018Journal of Lower Genital Tract Disease18 citations Open access
Semantic Scholar
Urine test for EGFR analysis in patients with non-small cell lung cancer.
A. Franovic, V. Raymond, M. Erlander, K. Reckamp
2017Journal of Thoracic Disease18 citations Open access
Semantic Scholar
Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma.
H. Husain, K. Kosco, C. Vibat, V. Meļņikova +4 more
201513 citations
Semantic Scholar
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
J. Goldman, C. Karlovich, L. Sequist, V. Meļņikova +23 more
2018JCO Precision Oncology11 citations
Semantic Scholar
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
R. Affatato, M. Chiappa, F. Guffanti, F. Ricci +6 more
2022Therapeutic Advances in Medical Oncology8 citations Open access
Semantic Scholar
MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
H. Wakelee, V. Meļņikova, C. Karlovich, S. Gadgeel +22 more
20176 citations Open access
Semantic Scholar
36ODETECTION OF EGFR T790M MUTATION IN URINARY CIRCULATING TUMOR DNA FROM METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS
H. Husain, K. Kosco, S. Guerrero, T.-T. Lu +3 more
20155 citations Open access
Semantic Scholar
436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
D. Ahn, M. Erlander, M. Ridinger, E. Samuelsz +3 more
20204 citations Open access
Semantic Scholar
Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer.
J. Johansen, C. Vibat, D. Calatayud, B. Jensen +5 more
20154 citations
Semantic Scholar
Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer
T. Bentley, B. Schroeder, C. Schnabel, M. Erlander +3 more
2014Journal of Medical Economics4 citations Open access
Semantic Scholar
Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.
F. Janku, C. Vibat, G. Falchook, S. Piha-Paul +12 more
20144 citations
Semantic Scholar
Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients.
O. Abdel-Wahab, E. Diamond, Minal A. Patel, Veronica R. Holley +11 more
20144 citations
Semantic Scholar
A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
David J. Einstein, A. Choudhury, P. Saylor, L. Werner +3 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
Abstract CT102: Phase Ib safety, preliminary anti-leukemic activity and biomarker analysis of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed or refractory acute myeloid leukemia
A. Zeidan, P. Becker, A. Spira, Prapti A. Patel +7 more
2019Clinical Trials3 citations
Semantic Scholar
Abstract 1885: Selective Polo-like Kinase 1 (PLK1) inhibitor PCM-075 is highly active alone and shows synergy when combined with FLT3 inhibitors in models of acute myeloid leukemia (AML)
K. Kosco, M. Ridinger, Penn Whitley, P. Croucher +2 more
2018Experimental and Molecular Therapeutics3 citations
Semantic Scholar
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score
Piiha-Lotta Jerevall, J. Brock, Juan A. Palazzo, T. Wieczorek +9 more
2018Breast Cancer Research and Treatment3 citations
Semantic Scholar
Combination of selective polo-like kinase 1 (PLK1) inhibitor PCM-075 with abiraterone in prostate cancer and non-androgen-driven cancer models.
J. C. Patterson, S. Varmeh, M. Erlander, M. Yaffe
20183 citations
Semantic Scholar
Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.
F. Janku, C. Vibat, G. Falchook, Helen J. Huang +16 more
20153 citations
Semantic Scholar
Abstract 2019: Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)
P. Croucher, E. Samuelsz, Latifa Hassaine, Brittany M. Ross +3 more
2020Clinical Trials2 citations
Semantic Scholar
Abstract CT235: A phase 1b/2 study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)
A. Barzi, H. Lenz, E. Samuelsz, M. Ridinger +3 more
2020Tumor Biology2 citations
Semantic Scholar
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC).
D. Ahn, A. Barzi, M. Ridinger, E. Samuelsz +3 more
2020Journal of Clinical Oncology2 citations
Semantic Scholar
A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer in patients with a KRAS mutation
H. Lenz, D. Ahn, M. Erlander, A. Barzi
2019Annals of Oncology2 citations Open access
Semantic Scholar
Abstract P6-01-10: Prognostic significance of breast cancer index (BCI) in node-positive hormone receptor positive early breast cancer: NCIC CTG MA.14
D. Sgroi, P. Goss, J. Chapman, E. Richardson +8 more
20152 citations
Semantic Scholar
Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations.
Jason C. Poole, C. Vibat, L. Benesova, B. Belšánová +4 more
20152 citations
Semantic Scholar
Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.
J. Johansen, C. Vibat, Saege A. Hancock, I. Chen +7 more
20152 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Vibat×13
Invite
C. Vibat — researcher profile on SciRah
M. Ridinger×13
Invite
M. Ridinger — researcher profile on SciRah
C. Schnabel×8
Invite
C. Schnabel — researcher profile on SciRah
K. Kosco×8
Invite
K. Kosco — researcher profile on SciRah

×7

Invite

Yi Zhang — researcher profile on SciRah

Invite

E. Samuelsz — researcher profile on SciRah

Latifa Hassaine×6

Invite

Latifa Hassaine — researcher profile on SciRah

Invite

F. Janku — researcher profile on SciRah

Invite

D. Sgroi — researcher profile on SciRah

B. Schroeder×5

Invite

B. Schroeder — researcher profile on SciRah

Invite

K. Reckamp — researcher profile on SciRah

Jason C. Poole×5

Invite

Jason C. Poole — researcher profile on SciRah